Jesse Silveira (MayoMobile)

Space & Biotech Intelligence

[Oliver Alexander @OAlexanderDK]

The dead VDV from Hostomel seeing the U.S. conduct a successful 3 hour heliborne special military operation.

[Visegrád 24 @visegrad24]

The Russian Air Force murdered hundreds of women, children and elderly when it bombed the Mariupol Drama Theatre on March 16th 2022 during the Siege of Mariupol.

Russia reopened it today and there are now Russians there dancing on the victims’ bones

[Visegrád 24 @visegrad24]

Today is the 3rd anniversary of the shocking murder of the Ukrainian prisoner-of-war Oleksandr Matsievskyi.

Captured at Bakhmut, the Russians forced him to dig his grave & say some final pleading words.

Instead, he took a last drag on his cigarette and said “Glory to Ukraine”

[Jesse Silveira (MayoMobile) @SOTCanalytics]

@ZM2514 @AnavexLifeSci @alzassociation @carlkestens Technically the science behind CRTX (I believe now known as Lighthouse) is sound. The problem is it seems to be only applicable to Alzheimer’s or Alzheimer’s-like patients with niche pathogenesis. Net good, but not for my investment. CGTX is a good option.

[Jesse Silveira (MayoMobile) @SOTCanalytics]

@AnavexLifeSci is potentially being rendered an approval decision by the #EMA this week for their oral Alzheimer’s therapy. But you wouldn’t have anything to say about that, would you @alzassociation?

[Jesse Silveira (MayoMobile) @SOTCanalytics]

@BmfReports Also, Anavex didn’t submit to EMA for Rett so..

[Jesse Silveira (MayoMobile) @SOTCanalytics]

@BmfReports The following is uninformed and untrue:

“EMA Rejection Incoming: Based on EMA guidance documents, historical precedent, and statistical review, Anavex’s application for blarcamesine is structurally non-approvable in its current form.”

[Jesse Silveira (MayoMobile) @SOTCanalytics]

@adamfeuerstein Your recent postings on $AVXL remind me of how I can’t watch super cringe shows/movies without pausing periodically to take a break. Try doing whatever you like to the price, but it’s embarrassingly obvious that you’re attempting to manipulate it. PAUSE.

[Jesse Silveira (MayoMobile) @SOTCanalytics]

@NellRebowe @jbiolchem

[Jesse Silveira (MayoMobile) @SOTCanalytics]

@NellRebowe @jbiolchem An excellent review of autophagy and the criticality of regulating ULK1

[Jesse Silveira (MayoMobile) @SOTCanalytics]

@SecKennedy #Alzheimer’s is caused by acidification alterations at the lysosome. As a result of DNA damage and mitochondrial dysregulation (aging) and calcium malfunctions. This is proven. Please investigate lysosomal maintenance, ER stress, and autophagy.

[Jesse Silveira (MayoMobile) @SOTCanalytics]

@yucanuck08 @alzassociation @TheADDF Indeed, and it’s about time!

[however, I’ve attended enough AAIC to know that the AA has a serious bias for anti amyloid mechanisms and has sensationalized mAb efficacy to no end. I can’t speak for financing in detail]

[Jesse Silveira (MayoMobile) @SOTCanalytics]

@TalNurielPhD @alzassociation There are proven mechanisms decades earlier than amyloid.

[Jesse Silveira (MayoMobile) @SOTCanalytics]

@jesse_brodkin Looks like you ‘inspired’ a world-renowned Alzheimer’s researcher to open-palm slap you: https://t.co/3sZkEIz4Gw

[Visegrád 24 @visegrad24]

On April 1st 2022, the internet was flooded with videos of Ukrainian civilians murdered in the Bucha Massacre

The town had been liberated a day earlier

Dozens of bodies were seen on the city’s streets, many of them with their hands tied behind their back

[Jesse Silveira (MayoMobile) @SOTCanalytics]

@adpdnet Check out @AnavexLifeSci open label extension data for their 2b/3 #Alzheimer’s trial, released Saturday! #Blarcamesine
#SIGMAR1

https://t.co/kN3zcLshXQ

[Jesse Silveira (MayoMobile) @SOTCanalytics]

@tedcruz, @MikeLeeforUtah, @RepChipRoy

Assuming approval by the European Medicines Agency, would you say this drug would fit criteria to be evaluated by the potentially forthcoming #RESULT Act?

@MartyMakary @RobertKennedyJr
@AnavexLifeSci

[Jesse Silveira (MayoMobile) @SOTCanalytics]

#Anavex Life Science’s #SIGMAR1 agonist supersedes cognitive and brain volume preservation over anti-amyloid treatments #Kisunla and #Leqembi in early #Alzheimer patients.

Under eval at #EMA, the drug targets disease 10-20 years prior to #amyloid.

[Jesse Silveira (MayoMobile) @SOTCanalytics]

Unprecedented for a registration-level Alzheimer’s therapy, the drug exceeded clinically meaningful thresholds for ADAS-COG13, and exhibited robust #neuroprotection, including increased frontal & parietal lobe volume over baseline.

https://t.co/kN3zcLshXQ